Background: The benefits of intravenous tissue plasminogen activator (tPA) in acute ischemic
Tissue plasminogen activator (tPA) is a proven intervention for acute ischemic stroke patients. 1, 2 The benefit of intravenous tPA in acute ischemic stroke is strongly time dependent. Analysis of pooled data from 6 large randomized tPA trials showed greater neurological improvement at 90 days with earlier tPA treatment. 3 The therapeutic benefit of tPA is greatest when given early after ischemic stroke onset and declines over 3 to 4.5 hours. [3] [4] [5] [6] Because of the importance of rapid treatment, national guidelines recommend that hospitals complete the clinical and imaging evaluation of acute ischemic stroke patients and initiate intravenous tPA therapy within 60 minutes of patient arrival in those without contraindications. 2, [7] [8] [9] Despite the proven benefits, guidelines recommendations, and explicit goals for timely administration of intravenous tPA, the frequency, patient and hospital characteristics, temporal trends, and outcomes of ischemic stroke with door-to-needle times ≤ 60 minutes have not been well studied in the US or elsewhere. To address this need, the Get With The Guidelines-Stroke national registry was analyzed to determine the presenting characteristics of acute ischemic stroke patients treated with intravenous tPA within 3 hours of symptom onset in whom a door-toneedle time ≤ 60 minutes was achieved, patient and hospital characteristics associated with doorto-needle times ≤ 60 minutes, hospital level variation in door-to-needle times, in-hospital clinical outcomes, and temporal trends in timely thrombolytic care.
METHODS
The American Heart Association and American Stroke Association (AHA/ASA) launched the Get With The Guidelines-Stroke initiative focused on the redesign of hospital systems of care to improve the quality of care for patients with stroke and transient ischemic attack. 10, 11 Details of the design and conduct of the Get With The Guidelines-Stroke program have been previously described. 11 Get With The Guidelines uses a Web-based patient management tool (PMT, Table I in the online-only Data Supplement. and overall tPA complications rates were also lower ( for the tPA complication of intracranial hemorrhage for patients with door-to-needle times ≤ 60 minutes compared with those with door-to-needle times >60 minutes.
DISCUSSION
Despite the proven benefits of timely administration of tPA for acute ischemic stroke and national goals, our analysis demonstrates that a minority of patients treated with intravenous tPA receive this therapy within 60 minutes of arrival. Older patients, black patients, women and those with less severe strokes or arriving during off-hours were particularly less likely to receive timely care. Additionally, hospitals with less experience in providing tPA to ischemic stroke patients were less likely to provide thrombolytic therapy within 60 minutes. This study is also important in finding only modest improvements in the timely administration of tPA over calendar time or duration of program participation. Given the slow progress in achieving faster door-to-needle times and the large remaining 'gap,' we believe these data support the need for a collaborative national campaign to improve timely treatment with intravenous tPA.
Data supporting the benefits of timely intravenous tPA on acute ischemic stroke outcomes in the setting of clinical trials are clear. [1] [2] [3] [4] [5] [6] Time to treatment with intravenous tPA is an important determinant of 90 day and 1 year functional outcomes in acute ischemic stroke. In a pooled analysis of 6 randomized placebo-controlled trials of intravenous tPA treatment started within 360 minutes of onset of stroke in 2775 patients, the odds of a favorable 3-month outcome increased as onset to treatment decreased. 3 Odds for improved functional outcomes were 2. Coalition's target for Primary Stroke Centers is to achieve a door-to-needle time within 60 minutes in 80% or more of patients. minutes. 14 In the two NINDS-tPA trials, the median door-to-needle was 64 minutes despite the need to obtain research informed consent by virtue of trial participation. 1 Select centers have reported mean door-to-needle times well below 60 minutes, including 50 minutes in Cologne, Germany and 38 minutes in Bergen, Norway. 15, 16 Many of these are dedicated stroke centers that benefit from regionalization of acute stroke care.
In the GWTG-Stroke dataset, the most powerful independent determinants of door-to-needle times ≤ 60 minutes were greater severity of stroke deficits on the NIHSS and higher annual hospital volume of tPA patients. Certain patient characteristics and comorbid conditions like diabetes and atrial fibrillation were independently associated with less timely administration of thrombolytic therapy. It is of concern that older patients, women, and black patients were less likely to receive timely administration of tPA. It is also notable that the symptom onset to arrival times were shorter in patients with door-to-needle times >60 minutes suggesting that hospitals were taking a more relaxed approach to the administration of tPA in earlier arriving patients.
Encouraging in our study were observations that achievement of door-to-needle times within 60 minutes was highest at hospitals with a larger annual volumes of intravenous tPA and that certain centers were able to achieve door-to-needle ≤ 60 minutes in the majority of patients. The number of hospitals with greater experience administering tPA is likely to increase in coming years due to the regionalization of emergency stroke care in the US with direct routing of patients to designated stroke centers and the emergence into practice of a generation of treatment-oriented emergency physicians, stroke neurologists and dedicated inpatient neurohospitalists. 17 The finding that the length of time participating in the GWTG-Stroke Program and The Joint Commission Primary Stroke Center Certification were not independently associated with an increase in the proportion of patients with door-to-needle times ≤ 60 minutes of arrival demonstrates the need to expand the focus of GWTG beyond efforts to increase tPA use among eligible patients. To this end, attention should turn to revising aspects of the GWTG-Stroke toolkit, intervention strategies, and recognition system to better highlight the importance of this door-to-needle target and provide best practice strategies for its achievement.
Successful efforts to accelerate door-to-needle times in acute ischemic stroke have been previously reported. [17] [18] [19] [20] [21] [22] These include pre-arrival notification by emergency medical service providers, written protocols for acute triage and patient flow, single call systems to activate all stroke team members, CT or MRI scanner clearance as soon as center is made aware of an incoming patient, locating the CT scanner in the Emergency Department, storage and rapid access to thrombolytic drug in the Emergency Department, collaboration in developing treatment pathways among physician, nurses, pharmacists, and technologists from Emergency Medicine, Neurology, and Radiology, and continuous data collection to drive iterative system improvement. [17] [18] [19] [20] [21] [22] It is also recommended that stroke programs continually evaluate their performance using quality improvement methods to ensure that eligible patients are evaluated and treated in a timely manner. 9 Although there may be concerns that attempting to achieve shorter door-to-needle times may lead to rushed assessments, dosing errors, and greater likelihood of complications, 17 in this study there was no evidence of worse in-hospital outcomes or increased bleeding complications from tPA for patients with door-to-needle times ≤ 60 minutes compared with those with door-to-needle times >60 minutes. In-hospital mortality was lower among those patients treated in a more timely fashion, even after extensive risk adjustment. Lower mortality has not been previously reported with more timely tPA therapy within the first three hours after stroke onset, so this finding should be interpreted cautiously and should be replicated in independent datasets. This finding is, however, consonant with meta-analysis data indicating that late thrombolytic therapy beyond 3 hours after onset increases mortality while earlier thrombolytic therapy within 3 hours does not. 23, 24 Importantly, the rate of symptomatic intracerebral hemorrhage in tPA treated patients with door-to-needle time within 60 minutes was 4.7%, lower than the 5.6% rate of reported in patients with door-to-needle above 60 minutes. These rates may also compare favorably to those observed in the NINDS trial (6.4%) and other phase IV studies. 1 These findings suggest that more rapid reperfusion therapy can be achieved without compromising short-term clinical outcomes.
This study identifies substantial opportunities nationally for improvement in the speed of tPA therapy initiation in acute ischemic stroke patients. Once patients with ischemic stroke have arrived at the hospital, it is incumbent upon the hospital to perform rapid diagnostic evaluation/imaging and, in eligible patients without contraindications, promptly initiate intravenous tPA therapy. 5, 9 It is important to acknowledge that a door-to-needle time number of additional factors that may be important in timely reperfusion were not captured in Get With The Guidelines-Stroke and could not be analyzed. These include pre-hospital notification by EMS, existence of a regional stroke system of care with routing of stroke patients directly to designated stroke centers, use of stroke pathways, availability of stroke neurologists, location of CT or MRI scanners in the Emergency Department, and timely feedback of performance. 17 A number of factors that influence in-hospital clinical outcomes or complications of tPA such as blood pressure control, adherence to dosing protocols, and early use of antiplatelet therapy were not collected or adjusted for. 2 NIHSS was not documented in 16.6% of patients, though findings for door-to-needle times and outcomes were similar in models with and without NIHSS. Residual measured and unmeasured confounding variables may have influenced some or all of the findings. As a result of the large sample size, some small differences in absolute terms are still highly statistically significant. Finally, no data on post discharge strokerelated outcomes are currently collected in the Get With The Guidelines-Stroke Program so the longer-term impact of door-to-needle times within 60 minutes on functional outcomes could not be determined.
CONCLUSIONS
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